secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0001558370-24-014184
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroBo completes Phase 2a MASH trial dosing; topline data due December 2024
----------------------------------------------------------------------------

- Last patient last visit in two-part Phase 2a trial of DA-1241, a GPR119 agonist for MASH.
- 95 of 109 randomized patients completed dosing across Part 1 (DA-1241 vs placebo) and Part 2 (DA-1241 + sitagliptin vs placebo).
- Primary endpoint: change from baseline in ALT at Week 16; secondary endpoints include lipid and safety measures.
- Topline data from both parts expected in December 2024; prior Phase 1 showed DA-1241 well tolerated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024014184/0001558370-24-014184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837024014184/nrbo-20241104x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-014184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer